Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
March 15, 2018 8:25 AM EDT
RBC Capital raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $14.00 (from $11.00) while maintaining an Outperform rating.
Analyst Gregory Renza notes the pipeline continues to progress as VGX-3100 continues to ramp up with broad CIN site expansion.
...
More
March 14, 2018 8:10 AM EDT
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting the objectives of the clinical study. Preliminary immunology data from the trial revealed that treatment of patients with INO-1800 resulted in the generation of T cells that recognized key components of the hepatitis B virus and reacted by making antiviral cytokines such as Interferon gamma, a protein believed to be linked to clearance of HBV... More
